ReviewInternational journal of nanomedicine2025
Research Progress on Nucleus-Targeting Carbon Nanoparticles for Tumor Imaging and Therapy.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Research Advances on Organelle-Targeted Drug Delivery Systems for the Treatment of Brain Tumors and Central Nervous System Inflammation.Pharmaceutics · 2026Review
- Nanocarbon as a Quantum Material for Biointerfaces and Magnetic Platforms in Theranostic Biomedicine in Oncology: A Critical Review.Biosensors · 2026Review
- Assessment of carbon nanoparticle suspension in sentinel lymph nodes biopsy for acral melanoma.World journal of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cell nucleus, as the central hub of cellular physiological activities, represents an effective target for cancer therapy. Targeting strategies aimed at the cell nucleus can enhance the delivery of more drugs into the tumor cell nucleus, thereby improving therapeutic efficacy. Such approaches can overcome the limitations of previous tissue- and cell-level treatments, such as insufficient specificity and excessive toxic side effects. Currently, researchers have integrated carbon nanoparticles (CNPs), therapeutic molecules, and nucleus-targeting components to construct various nucleus-targeted carbon nanoparticle delivery systems for tumor imaging and treatment. These systems not only increase drug concentration within the cell nucleus but also enable certain CNPs to utilize their intrinsic fluorescence for imaging monitoring. This review summarizes the latest classification progress of nucleus-targeted CNPs, their mechanisms of action in cancer-targeted diagnosis and treatment, and their applications in cancer therapy. Additionally, the article discusses the current challenges and future directions in this field, aiming to provide valuable reference information for precision cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.